PPT-Switch to NNRTI Switch to DOR/3TC/TDF

DRIVESHIFT Study Design Endpoints Primary of patients maintaining HIV RNA lt 50 cmL ITTsnapshot noninferiority of DOR3TCTDF at W48 and at W24 compared to continuation of cART. Fostemsavir. , . prodrug. of . temsavir. . (. attachment . inhibitor. ). AI438011 . Study. TAF (TFV . prodrug. ). Study . 292-0102. Study . 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objective. Non inferiority of EFV 400 mg at W48: % HIV RNA < 200 c/. mL. by modified intention to treat analysis (all randomised participants who received at least . STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Doravirine. /Lamivudine/TDF is Non-Inferior to . Efavirenz. /. Emtricitabine. /TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study. Kathleen E Squires. 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . 3. Hospital La Paz, Madrid, Spain; . 4. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, . David Geffen School of Medicine. at University of California Los Angeles. Antiretrovirals. in the Management of HIV Infection: Case-Based, Panel Discussion. From ES . Daar. , MD, at Los Angeles, Ca: April 22, 2013, IAS-USA. . –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. Dr Laura Oyiengo. NATIONAL AIDS STI CONTROL PROGRAM. MOH. BACKGROUND. As a country with the fourth largest Pediatric HIV epidemic in the world, Pediatricians need to be involved in programming, decision making and management of children and adolescent living with HIV and also in PMTCT programming.. Dr. Kay Mahomed. Netcare. Garden City Clinic. Mayfair West. 083 294 7007. 011 495 5243. overall_1_132245246515670924 columns_1_132245246515670924 . Goals of . Treatment. ART is the cornerstone of HIV . DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/r + ABC/3TC or TDF/FTC QD. Design. Randomisation*. 1: 1. Open-label. Objective. Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention to treat-exposed, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%, 80% power). SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.